The University of Michigan Comprehensive Cancer Center (UMCCC) requests renewal of its core grant in support of Senior Leadership, Programs, and Shared Core Facilities. A core grant to support the UMCCC was initially awarded by the NCI in 1988, with continuous funding since then. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of defined clinical, basic, and prevention programs in cancer research and the development of shared core resources. In 1997 the center moved into a new $88 million facility which houses the center's outpatient clinics as well as many of its research laboratories. The Cancer Center has continued to experience considerable growth over this grant period with 70 new faculty recruited and an 85% increase in NCI funding. The Cancer Center's 13 research programs include the basic research programs in Cancer Genetics, Cancer Cell Biology, Molecular Therapeutics, Radiation Sciences, and Molecular Imaging. Clinical research programs include Prostate/Urological, Breast, Leukemia/Lymphoma-BMT, Gl, Childhood Cancers, and Head & Neck cancers. The prevention programs include two programs: Biomedical Prevention and Socio-Behavioral. Support is requested for a total of 16 shared core facilities. These include Clinical Trials, Biostatistics, Tissue Procurement, Tumor Imaging, DNA Sequencing, Morphology, Flow Cytometry, Experimental Irradiation, Animal Facility, Transgenic Mouse, Vector Core, Immune Monitoring, cDNA Affymetrix and Microarray and three new cores including Proteomics, Bioinformatics, and Health Communications. Funds are also requested for development, planning and evaluation, and administration to support center goals. The Medical Center has made substantial commitments to the Cancer Center of approximately $175 million. Its 285 UMCCC members receive over $82 million in research funding, including over $37 million in annual direct NCI support. The UMCCC has had a major impact on cancer research as evidenced by publishing at least 315 articles in high impact journals, placing 52% of UMCCC intervention accruals onto investigator-initiated trials and consistently ranking among the top ten Cancer Centers nationally for NCI funding over this grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046592-20S2
Application #
7496821
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-06-01
Project End
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
20
Fiscal Year
2007
Total Cost
$59,280
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90

Showing the most recent 10 out of 1493 publications